We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata (MDSO) Reaches 52-Week High on New Partnership
Read MoreHide Full Article
Shares of Medidata Solutions, Inc. attained a new 52-week high of $55.61 on Sep 6, eventually closing a tad lower at $55.58. This represents strong year-to-date returns of about 12.8%. The S&P 500 has returned only about 7.0% during the same period.
New York-based Medidata Solutions is a leading global provider of hosted clinical development solutions. This Zacks Rank #3 (Hold) stock reported earnings of 13 cents in second-quarter 2016, beating the Zacks Consensus Estimate of 9 cents.
Key Growth Catalysts
The provider of cloud-based solutions for life sciences witnessed the spike in share prices after it announced the strategic commercial partnership with SHYFT Analytics. Per the agreement, the duo will focus on increasing access to healthcare data analytics in clinical trials. The partnership will focus on providing life sciences companies with the means to gather real world evidence data from electronic medical records. It would also provide health claims information traditionally collected from clinical trials.
Going forward, we feel the growing adoption of products like Medidata Payment solutions, Medidata Rave, Medidata Balance and Medidata’s Risk-Based Monitoring (RBM) solutions will likely drive revenues. The professional services and subscription revenues are also enhancing the growth opportunities of the company.
Medidata Solutions’ focus on Medidata Payments, a cloud-based payment technology and an add-on to its leading Medidata Clinical Cloud was also a sensible move. Notably, Medidata Solutions has 17 out of the top 25 global Pharma companies as enterprise customers, demonstrating its accomplishment in the space. Medidata Payments is likely to fortify its position by streamlining trial processes to a considerable extent.
For full-year 2016, Medidata expects total revenue between $450.0 million and $474.0 million at constant currency. Professional services revenues are likely to be in the band of $68 million to $70 million. Non-GAAP operating income is expected in the range of $102.0–$109.0 million.
Stocks to Consider
Some better-ranked stocks in the broader medical sector are CryoLife Inc. , Masimo Corp. (MASI - Free Report) and Quidel Corp. (QDEL - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medidata (MDSO) Reaches 52-Week High on New Partnership
Shares of Medidata Solutions, Inc. attained a new 52-week high of $55.61 on Sep 6, eventually closing a tad lower at $55.58. This represents strong year-to-date returns of about 12.8%. The S&P 500 has returned only about 7.0% during the same period.
New York-based Medidata Solutions is a leading global provider of hosted clinical development solutions. This Zacks Rank #3 (Hold) stock reported earnings of 13 cents in second-quarter 2016, beating the Zacks Consensus Estimate of 9 cents.
Key Growth Catalysts
The provider of cloud-based solutions for life sciences witnessed the spike in share prices after it announced the strategic commercial partnership with SHYFT Analytics. Per the agreement, the duo will focus on increasing access to healthcare data analytics in clinical trials. The partnership will focus on providing life sciences companies with the means to gather real world evidence data from electronic medical records. It would also provide health claims information traditionally collected from clinical trials.
Going forward, we feel the growing adoption of products like Medidata Payment solutions, Medidata Rave, Medidata Balance and Medidata’s Risk-Based Monitoring (RBM) solutions will likely drive revenues. The professional services and subscription revenues are also enhancing the growth opportunities of the company.
Price and Consensus
Price and Consensus | Quote
Medidata Solutions’ focus on Medidata Payments, a cloud-based payment technology and an add-on to its leading Medidata Clinical Cloud was also a sensible move. Notably, Medidata Solutions has 17 out of the top 25 global Pharma companies as enterprise customers, demonstrating its accomplishment in the space. Medidata Payments is likely to fortify its position by streamlining trial processes to a considerable extent.
For full-year 2016, Medidata expects total revenue between $450.0 million and $474.0 million at constant currency. Professional services revenues are likely to be in the band of $68 million to $70 million. Non-GAAP operating income is expected in the range of $102.0–$109.0 million.
Stocks to Consider
Some better-ranked stocks in the broader medical sector are CryoLife Inc. , Masimo Corp. (MASI - Free Report) and Quidel Corp. (QDEL - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>